Below are the most recent publications written about "Pharmacogenetics" by people in Profiles.
-
Blake KV, Hines LJ, Liu M, Myers RA, Baye JF, Cavanaugh KL, Duong BQ, Hulvershorn LA, Mathews CA, Murrough JW, Orlando LA, Petry NJ, Tillman EM, Sadeghpour A, Voora D, Block SL, Cicali EJ, Clermont S, Elwood EN, Harris EC, Nguyen KA, Ramos MA, Rosenman MB, Shroff N, Shuman S, Wyatt C, Horowitz CR, Volpi S, Singh R, Rider RA, Chakraborty H, Dexter PR, Johnson JA, Skaar TC, Cavallari LH, Peterson JF. Genotype-Guided Antidepressant Prescribing for Patients With Depression: A Randomized Clinical Trial. JAMA Netw Open. 2026 May 01; 9(5):e2610609.
-
Mart?nez-Jim?nez JE, Ortega-Lamp?n Y, Cedres-Rivera D, Heredia-Negr?n F, Roche-Lima A, Duconge J. Leveraging Machine Learning to Predict Warfarin Sensitivity in the Puerto Rican Population: A Pharmacogenomic Approach. Int J Environ Res Public Health. 2026 Mar 07; 23(3).
-
Roman YM. Pharmacogenomics and rare diseases: optimizing drug development and personalized therapeutics. Pharmacogenomics. 2025 Feb-Mar; 26(3-4):121-128.
-
Sharafshah A, Lewandrowski KU, Elman I, Baron D, Thanos PK, Hanna C, Gold MS, Badgaiyan RD, Cadet JL, Modestino EJ, Braverman ER, Dennen CA, Makale M, Sunder K, Murphy KT, Bowirrat A, Pinhasov A, Gondre-Lewis M, Gardner E, Sipple D, Jafari N, Zeine F, Khalsa J, Fiorelli RKA, Blum K. A Comprehensive 4-layered In Silico Pharmacogenomics Analysis of the Genetic Addiction Risk Severity (GARS) Test: Strong Genetic Evidence Supporting GARS as a Novel Personalized Pre-addiction Assessment Tool in the Opioid Crisis Era. Curr Pharm Biotechnol. 2025; 26(13):2153-2180.
-
Nu?ez-Medina HJ, Monero M, Torres LM, Leal E, Gonzalez-Sepulveda L, Mayor ?M, Renta JY, Gonz?lez-Garc?a ER, Gonz?lez A, Melin K, Scott SA, Rua?o G, Hernandez-Suarez DF, Duconge J. Implementing a pharmacogenomic-driven algorithm to guide antiplatelet therapy among Caribbean Hispanics: a non-randomised clinical trial. BMJ Open. 2024 09 05; 14(9):e084119.
-
Ioannou S, Beecham A, Gomez L, Dauer R, Khakoo N, Pascual L, Quintero M, Lopez J, Leavitt JS, Solis N, Ortega M, Deshpande AR, Kerman DH, Proksell S, Torres EA, Haritunians T, Li D, Abreu MT, McGovern DPB, McCauley JL, Damas OM. Ancestral Diversity in Pharmacogenomics Affects Treatment for Hispanic/Latine Populations With Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2025 May; 23(6):1008-1018.e7.
-
Zubiaur P, Rodr?guez-Antona C, Boone EC, Daly AK, Tsermpini EE, Khasawneh LQ, Sangkuhl K, Duconge J, Botton MR, Savieo J, Nofziger C, Whirl-Carrillo M, Klein TE, Gaedigk A. PharmVar GeneFocus: CYP4F2. Clin Pharmacol Ther. 2024 Oct; 116(4):963-975.
-
Hernandez-Martinez V, Duconge J, Rua?o G. An Expiration Date for Pharmacogenetic Test Results and Prescribing Guidance? J Appl Lab Med. 2023 07 05; 8(4):826-830.
-
Wen YF, Brundage RC, Roman YM, Culhane-Pera KA, Straka RJ. Population pharmacokinetics, pharmacodynamics and pharmacogenetics modelling of oxypurinol in Hmong adults with gout and/or hyperuricemia. Br J Clin Pharmacol. 2023 10; 89(10):2964-2976.
-
Niemsiri V, Rosenthal SB, Nievergelt CM, Maihofer AX, Marchetto MC, Santos R, Shekhtman T, Alliey-Rodriguez N, Anand A, Balaraman Y, Berrettini WH, Bertram H, Burdick KE, Calabrese JR, Calkin CV, Conroy C, Coryell WH, DeModena A, Eyler LT, Feeder S, Fisher C, Frazier N, Frye MA, Gao K, Garnham J, Gershon ES, Goes FS, Goto T, Harrington GJ, Jakobsen P, Kamali M, Kelly M, Leckband SG, Lohoff FW, McCarthy MJ, McInnis MG, Craig D, Millett CE, Mondimore F, Morken G, Nurnberger JI, Donovan CO, ?edegaard KJ, Ryan K, Schinagle M, Shilling PD, Slaney C, Stapp EK, Stautland A, Tarwater B, Zandi PP, Alda M, Fisch KM, Gage FH, Kelsoe JR. Focal adhesion is associated with lithium response in bipolar disorder: evidence from a network-based multi-omics analysis. Mol Psychiatry. 2024 01; 29(1):6-19.